Eli Lilly says new GLP-1 pill for diabetes and weight loss effective in study, will seek FDA approval
Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses.
Lilly